Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development July 15, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced July 15, 2026
FDA Clears IND Application for LTZ-232 to Treat Advanced Metastatic CRC and Other Solid Tumors July 15, 2026
Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors July 7, 2026
Positive Interim Ph 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability of PAS-004, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Announced July 7, 2026
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies June 30, 2026
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors June 30, 2026
Enhertu approved in the EU for patients with previously treated HER2+ve metastatic solid tumours June 30, 2026
First Patient enrolled in Ph 1/2 Trial Evaluating PM54 Plus Pembrolizumab in Advanced Solid Tumors June 30, 2026
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Gen T-cell Engaging Multispecific Antibodies June 23, 2026
Antengene Announces Exclusive License Agreement with K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE June 23, 2026
IND application for HLX3902 approved in China for treatment of metastatic CRPC and solid tumors June 23, 2026
Positive Pre-IND Feedback from Received US FDA for CLD-401; IND enabling studies to continue with IND submission targeted by end of 2026 June 23, 2026
Updated clinical findings from GEP-NET patients treated with ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE) announced June 17, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares June 17, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform June 10, 2026
Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics June 2, 2026
